Corvus Pharmaceuticals (CRVS) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed Oric Pharmaceuticals (ORIC) over the past year, gaining 12.8% versus a loss of 36.7%. Over five years, CRVS leads with a +183.6% price change compared with -48.6% for ORIC. Corvus Pharmaceuticals is the larger company by market cap ($815.7 million vs $764.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | ORIC |
|---|---|---|
| Share price | $9.67 | $7.36 |
| Market cap | $815.69M | $764.94M |
| 1-day change | -3.40% | -4.42% |
| YTD return | +25.58% | -10.02% |
| 1-year return | +12.84% | -36.66% |
| 5-year return | +183.58% | -48.64% |
| EPS (TTM) | $-0.72 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-15.28M | $-129.47M |
| 52-week high | $26.95 | $14.68 |
| 52-week low | $6.39 | $7.23 |
| Distance from 52-week high | -64.12% | -49.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +225.75% | +194.97% |
| Average volume | 1.05M | 1.59M |
| Shares outstanding | 84.35M | 103.93M |
| Employees | 37 | 111 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed ORIC by 49.5 percentage points over the past year.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
CRVS vs ORIC FAQ
Which is bigger, Corvus Pharmaceuticals or Oric Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $815.69M compared with $764.94M for Oric Pharmaceuticals (ORIC).
Which stock has performed better over the past year, CRVS or ORIC?
CRVS returned +12.84% over the past 12 months, compared with -36.66% for ORIC (price return, excluding dividends). Past performance does not predict future results.
Are Corvus Pharmaceuticals and Oric Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.